84 related articles for article (PubMed ID: 19777390)
1. The significance of new somatostatin analogs as therapeutic agents.
Zatelli MC; degli Uberti E
Curr Opin Investig Drugs; 2009 Oct; 10(10):1025-31. PubMed ID: 19777390
[TBL] [Abstract][Full Text] [Related]
2. Perspectives of new potential therapeutic applications of somatostatin analogs.
Pawlikowski M; Melen-Mucha G
Neuro Endocrinol Lett; 2003; 24(1-2):21-7. PubMed ID: 12743527
[TBL] [Abstract][Full Text] [Related]
3. In vitro testing of new somatostatin analogs on pituitary tumor cells.
Zatelli MC; Ambrosio MR; Bondanelli M; degli Uberti EC
Mol Cell Endocrinol; 2008 May; 286(1-2):187-91. PubMed ID: 18243520
[TBL] [Abstract][Full Text] [Related]
4. Novel heptapeptide somatostatin analog displays anti-tumor activity independent of effects on growth hormone secretion.
Murphy WA; Taylor JE; Moreau JP; Coy DH
Pept Res; 1989; 2(1):128-32. PubMed ID: 2577697
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
Grozinsky-Glasberg S; Shimon I; Korbonits M; Grossman AB
Endocr Relat Cancer; 2008 Sep; 15(3):701-20. PubMed ID: 18524947
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of somatostatin.
Pyronnet S; Bousquet C; Najib S; Azar R; Laklai H; Susini C
Mol Cell Endocrinol; 2008 May; 286(1-2):230-7. PubMed ID: 18359151
[TBL] [Abstract][Full Text] [Related]
7. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.
Weckbecker G; Raulf F; Bodmer D; Bruns C
Yale J Biol Med; 1997; 70(5-6):549-54. PubMed ID: 9825482
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
9. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
Zatelli MC; Piccin D; Vignali C; Tagliati F; Ambrosio MR; Bondanelli M; Cimino V; Bianchi A; Schmid HA; Scanarini M; Pontecorvi A; De Marinis L; Maira G; degli Uberti EC
Endocr Relat Cancer; 2007 Mar; 14(1):91-102. PubMed ID: 17395978
[TBL] [Abstract][Full Text] [Related]
10. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential.
Lewis I; Bauer W; Albert R; Chandramouli N; Pless J; Weckbecker G; Bruns C
J Med Chem; 2003 Jun; 46(12):2334-44. PubMed ID: 12773038
[TBL] [Abstract][Full Text] [Related]
11. Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides.
Raynor K; Murphy WA; Coy DH; Taylor JE; Moreau JP; Yasuda K; Bell GI; Reisine T
Mol Pharmacol; 1993 Jun; 43(6):838-44. PubMed ID: 8100350
[TBL] [Abstract][Full Text] [Related]
12. Future clinical prospects in somatostatin/cortistatin/somatostatin receptor field.
Dalm VA; Hofland LJ; Lamberts SW
Mol Cell Endocrinol; 2008 May; 286(1-2):262-77. PubMed ID: 17942217
[TBL] [Abstract][Full Text] [Related]
13. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors.
Kvols LK; Woltering EA
Anticancer Drugs; 2006 Jul; 17(6):601-8. PubMed ID: 16917205
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
Szepeshazi K; Schally AV; Nagy A; Wagner BW; Bajo AM; Halmos G
Cancer; 2003 Oct; 98(7):1401-10. PubMed ID: 14508826
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine-immune interactions: the role of cortistatin/somatostatin system.
Ferone D; Boschetti M; Resmini E; Giusti M; Albanese V; Goglia U; Albertelli M; Vera L; Bianchi F; Minuto F
Ann N Y Acad Sci; 2006 Jun; 1069():129-44. PubMed ID: 16855140
[TBL] [Abstract][Full Text] [Related]
16. [Somatostatin, somatostatin analogs and their clinical use].
Krsek M
Cas Lek Cesk; 2003 Mar; 142(3):134-8; discussion 139. PubMed ID: 12756839
[TBL] [Abstract][Full Text] [Related]
17. Characterization of cloned somatostatin receptors SSTR4 and SSTR5.
Raynor K; O'Carroll AM; Kong H; Yasuda K; Mahan LC; Bell GI; Reisine T
Mol Pharmacol; 1993 Aug; 44(2):385-92. PubMed ID: 8102785
[TBL] [Abstract][Full Text] [Related]
18. Potential indications for somatostatin analogs in Cushing's syndrome.
Arnaldi G; Polenta B; Cardinaletti M; Boscaro M
J Endocrinol Invest; 2005; 28(11 Suppl International):106-10. PubMed ID: 16625858
[TBL] [Abstract][Full Text] [Related]
19. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptors in the nucleus accumbens selectively mediate the stimulatory effect of somatostatin on locomotor activity in rats.
Raynor K; Lucki I; Reisine T
J Pharmacol Exp Ther; 1993 Apr; 265(1):67-73. PubMed ID: 8097248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
